Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHO plan on fake medicines could signal retreat from IMPACT

This article was originally published in SRA

Executive Summary

In a move that could herald a reduction in the World Health Organization's controversial involvement in the IMPACT anti-counterfeiting initiative, the body is to set up a new, member state-run mechanism to tackle the problem of substandard, falsified and counterfeit medicines1.

You may also be interested in...



Coronavirus Notebook: WHO’s Plan For Vaccine Manufacturing In Lower-Income Countries, UK Urged To Back IP Waiver

The UK’s independent vaccines committee has finalized its recommendations for the second phase of the COVID-19 vaccination program, and safety issues with several vaccines are still hitting the headlines.

Coronavirus Notebook: Vaccine Shortage Fears Heightened By Safety Scares, Italian Jab Enters Phase II/III

Russia’s Sputnik V vaccine gets the all-clear in India as the COVAX initiative hits the shortages speed bump. Also, two more antibody treatments are OKd for use in COVID-19 in the UK.

France To Replace AstraZeneca Booster With mRNA Jab In Under-55s

The French authorities believe that the “heterologous prime-boost” approach is justified in the case of people aged under 55 years who are due to receive their second dose of the AZ COVID-19 vaccine.

UsernamePublicRestriction

Register

PS116820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel